LivaNova PLC (NASDAQ:LIVN) Receives Average Rating of “Moderate Buy” from Analysts

LivaNova PLC (NASDAQ:LIVN) has been assigned an average rating of “Moderate Buy” from the ten brokerages that are currently covering the company, Marketbeat.com reports. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $80.75.

Several research analysts have recently commented on the company. Weiss Ratings upgraded LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research note on Thursday, May 7th. Robert W. Baird cut their price target on LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Mizuho lifted their price objective on shares of LivaNova from $85.00 to $90.00 and gave the stock an “outperform” rating in a research report on Thursday, May 7th. Barclays upped their price objective on shares of LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a report on Thursday, May 7th. Finally, KeyCorp raised their target price on shares of LivaNova from $83.00 to $92.00 and gave the stock an “overweight” rating in a research note on Monday, June 22nd.

Insiders Place Their Bets

In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $75.75, for a total transaction of $136,350.00. Following the completion of the sale, the director directly owned 7,228 shares in the company, valued at $547,521. This trade represents a 19.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.35% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On LivaNova

A number of institutional investors have recently modified their holdings of LIVN. Millennium Management LLC boosted its holdings in LivaNova by 17.3% in the 4th quarter. Millennium Management LLC now owns 3,484,082 shares of the company’s stock valued at $214,376,000 after purchasing an additional 514,268 shares during the period. Wellington Management Group LLP boosted its stake in shares of LivaNova by 83.5% in the third quarter. Wellington Management Group LLP now owns 2,345,516 shares of the company’s stock valued at $122,858,000 after buying an additional 1,067,349 shares during the period. Vanguard Group Inc. grew its position in LivaNova by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 2,332,051 shares of the company’s stock worth $143,491,000 after buying an additional 34,812 shares in the last quarter. AQR Capital Management LLC lifted its position in shares of LivaNova by 29.9% during the 4th quarter. AQR Capital Management LLC now owns 2,155,142 shares of the company’s stock valued at $132,606,000 after acquiring an additional 496,165 shares during the period. Finally, Dimensional Fund Advisors LP increased its stake in LivaNova by 2.1% in the first quarter. Dimensional Fund Advisors LP now owns 1,826,248 shares of the company’s stock valued at $116,067,000 after acquiring an additional 38,320 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

LivaNova Stock Down 0.5%

LivaNova stock opened at $83.58 on Wednesday. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.33 and a quick ratio of 1.11. The company’s 50-day moving average is $74.72 and its 200-day moving average is $67.94. The firm has a market capitalization of $4.59 billion, a PE ratio of 42.86 and a beta of 0.86. LivaNova has a fifty-two week low of $41.01 and a fifty-two week high of $85.27.

LivaNova (NASDAQ:LIVN) last issued its earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.13. The business had revenue of $362.26 million during the quarter, compared to the consensus estimate of $346.05 million. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. LivaNova’s revenue was up 14.3% on a year-over-year basis. During the same period last year, the business posted $0.88 EPS. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. Sell-side analysts anticipate that LivaNova will post 3.73 earnings per share for the current year.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.